Retrospective Study

Case series of COVID-19 patients from the Qinghai-Tibetan Plateau Area in China

Ji-Jie Li, Hui-Qiong Zhang, Pei-Jun Li, Zhi-Lan Xin, Ai-Qi Xi, Zhuo-Ma, Yue-He Ding, Zheng-Ping Yang, Si-Qing Ma

ORCID number: Ji-Jie Li 0000-0002-2928-7178; Hui-Qiong Zhang 0000-0002-0877-5885; Pei-Jun Li 0000-0002-1293-6207; Zhi-Lan Xin 0000-0001-8391-856X; Ai-Qi Xi 0000-0002-6671-8707; Zhuo-Ma 0000-0002-0360-6273; Yue-He Ding 0000-0002-3525-2422; Zheng-Ping Yang 0000-0002-6961-513X; Si-Qing Ma 0000-0001-8735-9486.

Author contributions: Li JJ, Li PJ, and Zhang HQ contributed to study conception and design; Li JJ, Li PJ, Zhang HQ, Xin ZL, Xi AQ, Zhuo-Ma, and Yang ZP analyzed and interpreted the data; Ma SQ drafted the manuscript; Li JJ revised the manuscript for important intellectual content; all authors gave final approval for submission of the manuscript.

Institutional review board statement: The clinical research protocol was approved by the Institutional Review Board and the Ethical Committee of the Qinghai fourth People’s Hospital and Institute (No. 20200401), which were in accordance with the ethical standards of our Institutional Review Board and with the 1975 Helsinki declaration (Revised 2010) and its later amendments or comparable ethical standards. Informed consent was waived by the Institutional Review Board.

Abstract

BACKGROUND
Coronavirus disease 2019 (COVID-19) is a serious infection caused by the new coronavirus severe acute respiratory syndrome coronavirus 2. The disease was first identified in December 2019 and has caused significant morbidity and mortality worldwide.

AIM
To explore the clinical characteristics and treatments for COVID-19 in the Qinghai-Tibetan Plateau Area in China.

METHODS
We retrospectively analyzed the blood cell counts (neutrophils and lymphocytes), blood gas analysis, and thoracic computed tomography changes of patients from Qinghai Province before, during, and after treatment (January 23, 2020 to February 21, 2020). In addition, we summarized and analyzed the information of critical patients. All data were analyzed using SPSS 17.0 (SPSS Inc., Chicago, IL, United States). The quantitative and count variables are represented as the mean ± SD and n (%), respectively.

RESULTS
the committee because of the retrospective nature of the study.

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** The authors declare that they have no competing interests to disclose.

**Data sharing statement:** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/License s/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Specialty type:** Respiratory system

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**
- Grade A (Excellent): 0
- Grade B (Very good): B
- Grade C (Good): 0
- Grade D (Fair): 0
- Grade E (Poor): 0

**Received:** March 26, 2021

**Peer-review started:** March 26, 2021

**First decision:** May 5, 2021

**Revised:** June 11, 2021

**Accepted:** July 5, 2021

**Article in press:** July 5, 2021

**Published online:** August 26, 2021

**P-Reviewer:** El-Arabey AA

The main symptoms and signs of patients with COVID-19 were fever, dry cough, cough with phlegm, difficulty breathing, and respiratory distress with a respiration rate ≥ 30 times/min, finger oxygen saturation ≤ 93% in the resting state, and oxyge

**CONCLUSION**

Our findings provide critical insight into assessing the clinical diagnosis and treatment for COVID-19 in the Tibetan plateau area.

**Key Words:** Qinghai; Plateau; COVID-19; Blood cell; Pneumonia; Case series

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Eighteen patients with coronavirus disease 2019, of whom three were critical and the rest were in a mild condition were enrolled. The main manifestations included fever, dry cough, and fatigue. Three patients developed difficulty breathing and had a fever and were eventually cured and discharged.

**Citation:** Li JJ, Zhang HQ, Li PJ, Xin ZL, Xi AQ, Zhuo Ma, Ding YH, Yang ZP, Ma SQ. Case series of COVID-19 patients from the Qinghai-Tibetan Plateau Area in China. World J Clin Cases 2021; 9(24): 7032-7042

**URL:** https://www.wjgnet.com/2307-8960/full/v9/i24/7032.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v9.i24.7032

**INTRODUCTION**

The novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) is an enveloped, non-segmented, positive-sense single-stranded RNA virus, causing a severe human and livestock coronavirus disease[1]. Since December 2019, the coronavirus disease 2019 (COVID-19) has swept the entire country of China. Clinical findings showed exuberant inflammatory responses, likely a leading cause of case fatality during SARS-CoV-2 infection, followed by other symptoms such as acute respiratory distress syndrome (ARDS) and immune dysfunction[2-4].

According to the statistics released by Johns Hopkins University on May 30, 2020, the number of confirmed cases in the world has reached 6003762, with 367356 deaths. Data shows that the United States is the country with the most serious epidemic, with 1764671 confirmed cases and 103605 deaths. Countries with more than 200000 confirmed cases are Brazil, Russia, the United Kingdom, Spain, and Italy. In addition, France, Germany, India, and Turkey have more than 130000 cumulative confirmed cases. Common symptoms include fever, fatigue, and dry cough and computed tomography (CT) shows that the lungs of most patients have a bilateral patchy shadow or ground-glass opacity[5-8]. Most patients receive anti-virus treatment (oseltamivir), many patients receive antibacterial treatment (moxifloxacin, ceftriaxone, and azithromycin), and glucocorticoid therapy[9]. Real-time reverse transcription-polymerase chain reaction (RT-PCR) is used for nucleic acid detection of the novel coronavirus[6,10]. It is suggested that the combination of repeated swab tests and CT scanning is helpful for the clinical diagnosis of COVID-19 when it is highly suspected of SARS-CoV-2 infection, but RT-PCR screening is negative[9,10]. The mechanisms of COVID-19 remain elusive, although respiratory virus-induced lung injuries are considered to be involved[11]. Toll-like receptors (TLRs) such as TLR3 and TLR9 are activated by viral RNA, leading to the activation of mesenchymal stem cells (MSCs)
that are associated with lung injuries[12]. MSCs can induce innate antiviral defenses and provide therapeutic benefits in COVID-19 patients. Studies showed that SARS-CoV-2 exploits the angiotensin-converting enzyme 2 (ACE2) receptor to enter the cells, which causes neurological tissue damage[13]. By now, scientists have proposed a hypothesis for the pathobiology and treatment of COVID-19. ACE2 is the receptor of coronavirus SARS-CoV-2, and reducing ACE1/ACE2 imbalance may blunt the morbidity and mortality of COVID-19[14]. The good news is that ANG II receptor blockers and ACE1 inhibitors can be rapidly tested in patients with COVID-19. The prognosis of most patients is good. Only individuals with poor immune function, such as the elderly, pregnant women, or those with serious basic diseases such as diabetes, coronary heart disease, and liver and kidney dysfunction, have a relatively rapid progression and higher severity. Some of these patients may become critically ill or even die[15,16].

Although the mechanisms and treatments for COVID-19 have been explored, there is no report of the treatments and clinical characteristics of COVID-19 patients in the Tibetan plateau area. The plateau is geographically defined as an extensive, flat land area with an altitude above 500 m and gentle slopes in the terrain. It is confirmed that an altitude above 3000 m can induce a significant biological effect in people living in the plateau area, which has been the study focus for high altitude medical research[17,18]. This manuscript reports case series of COVID-19 patients from the Qinghai-Tibetan Plateau Area in China, which will improve the understanding of COVID-19.

**MATERIALS AND METHODS**

**Study design and patients**

This was a retrospective case series of patients confirmed with COVID-19 at Qinghai fourth People’s Hospital and Xining Third People’s Hospital, which were designated hospitals for COVID-19 in Qinghai Province. The diagnostic criteria were based on pathogenic or serological evidence: (1) Positive real-time PCR test for SARS-CoV-2; (2) Viral whole-genome sequencing showing high homogeneity to SARS-CoV-2; and (3) Positivity for the specific immunoglobulin M antibody and immunoglobulin G (IgG) antibody in the serum SARS-CoV-2 test, a change of the SARS-CoV-2-specific IgG antibody from negative to positive, or titer rising ≥ 4 times in the recovery phase above that in the acute phase.

**Ethics**

The clinical research protocol was approved by the Institutional Review Board and the Ethical Committee of the Qinghai fourth People’s Hospital and Institute (No. 20200401), which were in accordance with the ethical standards of our Institutional Review Board and with the 1975 Helsinki declaration (revised in 2010) and its later amendments or comparable ethical standards.

**Treatments**

The patients were treated in compliance with the fifth edition of the treatment and diagnosis plan for COVID-19 published by the National Health Commission, as summarized below.

**General treatment:** Rest in bed in the isolation area with sufficient energy supply was suggested. Enhanced supportive care was given to maintain the homeostasis of water and electrolyte. (1) Oxygen was given in a timely manner to keep the airway moist. Once admitted, the patients were given oxygen at 2-5 L/min intranasally or through a face mask to ensure that the figure oxygen saturation was around 95%. And (2) Antiviral medication: Atomization inhalation of α-2b interferon (Bioway Biomedical Co. Ltd, Tianjin) was provided at a dose of 5 million units per time for adults, three times per day. Lopinavir/ritonavir (Kaletra; 200 mg/50 mg per tablet; approval No. H20170213; manufactured by AbbVie Deutschland GmbH & Co.KG, Germany) was given two tablets each time, twice a day. Children were given three tablets per day in total, twice a day. Moxifloxacin (0.4 g; Bayer Pharmaceuticals) was given orally or intravenously once a day. The Chinese medicine Xue Bi Jing (Chase Sun Pharmaceutical Co. Ltd, Tianjin) for injection was given intravenously at 50-100 mL once a day. The Chinese medicine Tan Re Qing (Kai Bao Pharmaceutical Co. Ltd, Shanghai) for injection was given intravenously at 10-30 mL once a day. Ribavirin (Ya Tai Pharmaceutical Co. Ltd, Zhejiang Province) was given intravenously at a dose of 500 mg per time, three times a day for adults. Vitamin C (2 g; Hasen Modern Pharma-
ceutical Co. Ltd, Shanghai) was given intravenously once a day. Oseltamivir 75 mg (Yichang HEC Changjiang Pharmaceutical Co., Ltd, Hubei Province) capsules were given orally twice a day. Thymalfasin (1.6 mg; ShuangCheng Pharmaceutical Co., Ltd, Hainan Province) was given by subcutaneous injection twice per week.

Treatments for patients in critical condition: (1) Oxygen inhalation: The patients were provided with a non-invasive ventilator (Phillips V60) to facilitate respiration, with the following parameters: Inspiratory pressure 10-12 cmH₂O, PEEP 4-8 cmH₂O, FiO₂ 35%-45%, and SpO₂ 95%. Prone position ventilation was initially used. The V60 non-invasive ventilators from Philips were used, with 4-6 cm H₂O pressure in the CPAP mode; (2) Steroid treatment: Methylprednisolone sodium succinate for injection (40-80 mg) (Haisco Pharmaceutical Co. Ltd, Liaoning Province) was given twice a day intravenously. The human immunoglobulin for injection (25 g) (Hualan Biological Engineering Inc., Shanghai) was given intravenously once a day for three successive days; (3) Fluid therapy: The daily fluid intake was kept below 800 mL to maintain a negative fluid balance; and (4) Plasma therapy: The three critical patients were given the plasma from cured patients intravenously twice, 50 mL each time.

Chinese medicine treatment: (1) Therapy 1: Astragalus 15 g, dried white Atractylodes rhizome 10 g, Saposhnikovia divaricata 10 g, Radix isatidis 15 g, honeysuckle 10 g, dried tangerine peel 8 g.m. and Eupatorium 10 g, one pack a day and decocted twice in water; (2) Therapy 2: Rhizoma Pinelliae Praeparata 9 g, dried tangerine peel 10 g, Codonopsis pilosula 15 g, Astragalus 30 g, Tuckahoe 15 g, Agastache rugosus 15 g, Fructusamomi 6 g, Cordatehouttuynia 30 g, Forsythia 20 g, Paeoniae Radix 15 g, Oyster 30 g, Fructus Aurantii 20 g, and Radix Isatidis 20 g, one pack a day and decocted twice in water. This therapy would help invigorate the circulation, reduce the disease-causing risks, and detoxify the body for recovery; and (3) Therapy 3: Rhizoma Pinelliae Praeparata 9 g, dried tangerine peel 10 g, Codonopsis pilosula 15 g, Astragalus membranaceus 30 g, smilax glabra rhizome 15 g, Pogostemon cablin 15 g, Fructusamomi 6 g, Cordatehouttuynia 30 g, Forsythia 20 g, Fried Forsythia 20 g, Eupatorium 20 g, dried ginger 10 g, Paeoniae Radix 15 g, and Oyster 30 g.

Criteria for discharge: The patient’s body temperature had to remain normal for at least 3 d. The respiratory symptoms greatly improved. The patient tested negative for pathogenic nucleic acids in two successive tests (at least 24 h apart). If all criteria were met, the patient could be discharged or transferred to the corresponding department to treat other diseases.

Laboratory analysis
Complete blood tests were performed before and after treatment, including blood cell count (including neutrophils and lymphocytes) and blood gas analysis. The equipment involved an Automated Erythrocyte Sedimentation Rate Analyzer (Monitor-100, Vital Diagnosis, Italy), Zybio-Q7 for determination of procalcitonin/C-reactive protein (ZybioInc, Chongqing), the blood gas analyzer ABL90 (Radiometer, Denmark), and Biochemical analyzer TBA-FX8 (TOSHIBA, Japan). Blood samples were drawn into ethylenediaminetetraacetic acid tubes and mixed well at venipuncture and again just before analysis. All measurements were commenced within 4 h after blood collection.

Statistical analysis
All data were analyzed using SPSS 17.0 (SPSS Inc., Chicago, IL, United States). The continuous and categorical variables are presented as the mean ± SD and n (%). Comparisons between two groups were examined using the two-sample t-test, and comparisons among multiple groups were examined using the F-test. The between-group comparisons of categorical variables were performed by Chi-square test. P < 0.05 was considered statistically significant.

RESULTS

Characteristics of the patients
Since the admission of the first confirmed case in Qinghai Province on January 23, 2020, 18 patients were confirmed with COVID-19, of whom three were in a critical condition, and the others were in a mild condition. Altogether 15 patients were admitted to Qinghai Fourth People’s Hospital, including the three in a critical condition, and three patients in mild condition were admitted to Xining Third People’s
Hospital. All 18 patients were discharged. No death occurred. The main manifestations included fever, dry cough, and fatigue. Three patients developed difficulty breathing.

**Clinical characteristic of the patients**

Regarding main symptoms and signs, 10 patients had a fever, 12 had a dry cough, five had cough with phlegm, three had difficulty breathing, three had respiratory distress with a respiration rate ≥ 30 times/min, three had finger oxygen saturation ≤ 93% in the resting state, and three had an oxygenation index less than 200 but greater than 100 (after altitude correction). Three (17%) out of the 18 patients developed difficulty breathing within an average of 11 d after disease onset, with oxygen saturation ≤ 93% and altitude-corrected oxygenation index less than 200 but greater than 100. These three cases were initially in a mild condition and were given intranasal oxygen inhalation and gradually progressed into critical or severe conditions.

Adjuvant examinations showed one patient with a reduced white cell count (6%) (< $4 \times 10^9$/L), six with reduced counts of lymphocytes (33%) (< $0.8 \times 10^9$/L), and one with an abnormal blood glucose level (Figure 1).

Thoracic CT revealed 13 cases with bilateral pneumonia, one with pneumonia in the left lung, three with pneumonia in the right lung, and one with no obvious pulmonary lesion.

A nasopharyngeal swab was collected when the patients did not have a fever or clinical symptoms for 3 d. A recheck was performed 24 h after the initial test. Sixteen cases turned out negative in the initial test, and two remained positive.

Sixteen out of the 18 cases were imported cases with a history of going to Wuhan for work, school, or family visits. Of all the imported cases, the first confirmed case in Qinghai worked for a company and developed symptoms 3 d after returning to Xining from Wuhan, and initially had a fever with a body temperature of 37.1 °C. On January 25, he was confirmed infected. A patient and his son lived in Wuhan and worked in the catering industry for a long time. They returned from Wuhan on January 16, 2020, and developed symptoms including cough, fever, and fatigue on that night. They attended a few events and were in contact with more than 300 people before their nasopharyngeal swab samples were tested positive in Qinghai Provincial Center for Disease Control and Prevention on January 28. Among those contact people, some cases were confirmed with COVID-19. Three were family cases, and five shared the same transportation. One of the two secondary infection cases was in close contact with a confirmed case, and the other case developed symptoms after being in contact with people returning from Wuhan. Among the 18 cases, 15 were from agricultural and pastoral areas (83%), and three were from urban areas (17%), including 12 males (67%) and six females (33%). The age ranged from 7 to 47 years old, with an average of 30.5 years old. Five cases were found to have underlying diseases: One with polymyositis (6%), two with hypertension (11%), two with tuberculosis (11%), and one with chronic hepatitis B (6%).

**Laboratory analysis**

The white blood cell count after treatment was not statistically meaningful because of the steroid treatment. The lymphocyte counts returned to normal after treatment.

**Characteristics of critical patients**

**Patient 1:** In a critical condition, was a 44-year-old man who used to work in the catering industry in Wuhan and was born in Qinghai province. He had hypertension. He had a fever with the highest body temperature of 39.5 °C when he returned from Wuhan and was eventually cured and discharged.

**Patient 2:** In a critical condition, was a 43-year-old man who was born and worked in Qinghai province. He had hypertension. He was the younger brother of patient 1 and was in close contact with him. He had a fever with the highest body temperature of 38.7 °C and was eventually cured and discharged.

**Patient 3:** In a critical condition, was a 26-year-old man who used to work in the catering industry in Wuhan and was born in Qinghai province. He had no underlying conditions. He had a fever with the highest body temperature of 37.8 °C when he came back from Wuhan and was eventually cured and discharged.

The dynamic blood gas analysis (Figure 1) and imaging manifestations of the critical patients before and after treatment (Figure 2) are shown.
Figure 1 Dynamic blood gas analysis of three critical patients. A: PCO\textsubscript{2}, lactic acid, and concentration of HCO\textsubscript{3} remained basically stable. O\textsubscript{2} partial pressure and O\textsubscript{2} saturation gradually increased. Total blood O\textsubscript{2} concentration gradually increased and remained stable; B: PCO\textsubscript{2} remained stable as the condition improved. O\textsubscript{2} partial pressure gradually increased and remained stable. O\textsubscript{2} saturation gradually increased. Lactic acid, concentration of HCO\textsubscript{3}, and total blood O\textsubscript{2} remained stable; C: PCO\textsubscript{2} remained stable as the condition improved. O\textsubscript{2} partial pressure and O\textsubscript{2} saturation gradually increased and remained stable. Lactic acid, concentration of HCO\textsubscript{3}, and total blood O\textsubscript{2} remained stable.

**DISCUSSION**

Since December 2019, COVID-19 has spread widely across China and all over the world. The virus is highly contagious and can target multiple organs. Therefore, it is
very difficult to treat the disease. The doctors in the isolation ward try their best to save the patients and fight the virus[19,20]. There has been no report of the treatments and clinical characteristics for COVID-19 patients in the Tibetan plateau area. We report a series of COVID-19 patients from the Qinghai-Tibetan Plateau Area in China, which will improve the understanding of COVID-19. Since the admission of the first confirmed case in Qinghai on January 23, 2020, there were 18 confirmed cases in total, of whom three were in critical condition. As of February 21, 2020, all patients were cured and discharged. No death was reported. There were only two secondary infection cases in Qinghai province, which could be due to its location in the east of the Qinghai-Tibet Plateau with high altitude, low atmospheric oxygen content, and high ultraviolet (UV) exposure.

In this study, we found that the most common symptoms of COVID-19 were fever, dry cough, and fatigue, consistent with the COVID-19 diagnostic criteria published by the National Health Commission of China[21-23]. Of all 18 COVID-19 patients in the
plateau area, no death was reported. The fatality of patients in the plateau area is significantly lower than the whole national average level, which might be associated with characteristics of the plateau area[24]. The plateau area is a low-pressure environment. At the altitude of 5500 m, both atmospheric pressure and oxygen partial pressure are decreased by 50% compared with those at the sea level, resulting in decreased oxygen partial pressure of pulmonary gas exchange and arterial oxygen saturation[25-27]. In addition, for every 100 m increase in altitude, the temperature drops by about 0.6 °C. The cold makes the oxygen consumption and oxygen demand and the body load increase, and promotes the occurrence and development of tissue hypoxia[28-30]. The humidity at an altitude of 3000 m is only 34% of that in the plain; at an altitude of 6000 m, it is only 5% of that in the plain. Hence, water loss from the body surface and respiratory tract in plateau area is higher than that in the plain area, especially during exercise. At the same time, due to the influence of diuretic factors such as hypoxia and cold, the water content of the body is reduced, resulting in the abnormal dryness of the respiratory mucosa and the whole-body skin, and symptoms such as pharyngitis, dry cough, epistaxis, and dry split skin are easy to occur.

The plateau area has strong radiation and strong ultraviolet, more than 2.5 times that in the plain. When the incident and reflection rays are superposed, the amount and intensity of the ultraviolet light received by the human body increase significantly, causing damage to the skin and eyes[31,32] but possibly contributing to a low viral transmission. Therefore, the only two secondary infection cases could be due to high altitude, low atmospheric oxygen content, and high UV exposure. Indeed, ultraviolet light can be used to decontaminate protective equipment such as single-use filtering face respirators[33,34]. A previous study suggested that the maximal COVID-19 death rates were observed in areas with a maximal temperature of 10.1 °C, maximal humidity of 55%, and a null UV index[35]. Although the temperature is cold in the plateau, humidity is far lower than 55%, and the UV index is elevated. The characteristics of patients in critical condition include mild disease onset but sudden exacerbation in about 2 wk. The high fever was significantly correlated with respiratory difficulty. Hypoxia caused by COVID-19 has a smaller effect on the patients’ heart rate and respiratory rate than that caused by other ARDS, contrary to our expectations[36]. It can be proposed that it is critical to provide oxygen treatment in advance as the hypoxia in the patients with COVID-19 is silent and deceptive.

SARS-CoV-2 has a potential impact on the heart, especially in patients with cardiovascular diseases, and the potential complications and death risk increase. Reasonable preventive measures are recommended. In the COVID-19 diagnosis and treatment guidelines, the following definitions have been made for the patients with severe and critical respiratory infection: Severe cases have respiratory distress, hypoxemia, or shock, and require oxygen therapy, while critical cases require respiratory support and have hypoxic respiratory failure, ARDS, and septic shock. Severe and critical patients often have respiratory difficulties caused by the infection, which is the main clinical manifestation of myocardial injury[37]. While atmospheric pressure and oxygen partial pressure are decreased by 50% in the plateau area, more attention must be paid to hypoxemia.

There are some limitations to this study. The sample size was small, with only 18 patients included. The age of patients ranged between 7-47 years old, with an average of 30.5 years old, and there were no neonatal or elderly patients. Because of the epidemic, no further study of the similarities and differences of the mechanisms was performed. Last, because of the retrospective design of the study, some data might be missing.

CONCLUSION

In this study, we collectively illuminate the epidemiological characteristics and treatments for COVID-19 patients from the Qinghai-Tibetan Plateau Area in China. Our findings provide critical insight into assessing the clinical diagnosis and treatment of COVID-19 in the plateau area, which will further improve the understanding of COVID-19.
ARTICLE HIGHLIGHTS

Research background
Coronavirus disease 2019 (COVID-19) is a serious infection caused by the new coronavirus severe acute respiratory syndrome coronavirus 2. The disease was identified in December 2019 and has caused significant morbidity and mortality worldwide.

Research motivation
Although the mechanisms and treatments for COVID-19 have been explored, there is no report of the treatments and clinical characteristics for COVID-19 patients in the Tibetan plateau area, which features a low temperature, low humidity, and high ultraviolet exposure.

Research objectives
To explore the clinical characteristics and treatments for COVID-19 in the Qinghai-Tibetan Plateau Area in China.

Research methods
This study retrospectively analyzed the blood cell counts (neutrophils and lymphocytes), blood gas analysis, and thoracic computed tomography changes of patients from Qinghai Province before, during, and after treatment (January 23, 2020 to February 21, 2020). In addition, we summarized and analyzed the information of critical patients.

Research results
This study included 18 patients with COVID-19 in the Qinghai-Tibetan Plateau Area. The main manifestations included fever, dry cough, and fatigue. Three patients developed difficulty breathing and had a fever. They were eventually cured and discharged. Of the 18 cases, only two had secondary infections and three developed a critical condition but were cured and discharged. All 18 patients were discharged, and no death occurred.

Research conclusions
This study collectively illuminates the epidemiological characteristics and treatments for COVID-19 patients from the Qinghai-Tibetan Plateau Area in China.

Research perspectives
Our findings provide critical insight into assessing the clinical diagnosis and treatment of COVID-19 in the plateau area, which will further improve the understanding of COVID-19.

REFERENCES
1 Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020; 92: 418-423 [PMID: 31967327 DOI: 10.1002/jmv.25681]
2 Li D, Chen Y, Liu H, Jia Y, Li F, Wang W, Wu J, Wan Z, Cao Y, Zong R. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study. Signal Transduct Target Ther 2020; 5: 62 [PMID: 32371949 DOI: 10.1038/s41392-020-0163-5]
3 Molloy EJ, Bearer CF. COVID-19 in children and altered inflammatory responses. Pediatr Res 2020; 88: 340-341 [PMID: 32244248 DOI: 10.1038/s41390-020-0881-y]
4 Vittori A, Lerman J, Cascella M, Gomez-Morad AD, Marchetti G, Marinangeli F, Picardo SG. COVID-19 pandemic acute respiratory distress syndrome survivors: pain after the storm? Anesth Analg 2020; 131: 117-119 [PMID: 32541584 DOI: 10.1213/ANE.0000000000004914]
5 Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]
6 Epidemiology Working Group for NCIP Emergency Response, Chinese Center for Disease Control and Prevention. Rapid investigation plan of clinical courses and key diagnosis and treatment equipment requirements for the patients of the 2019 Novel Coronavirus Pneumonia (COVID-19). Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41: 296 [PMID: 32294823 DOI: 10.3760/cma.j.issn.0254-6450.2020.03.002]
7 DU HZ, Hou XY, Miao YH, Huang BS, Liu DH. Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP). Chin J Nat Med 2020; 18: 206-210 [PMID: 32245590 DOI: 10.1016/S1875-5364(20)30022-4]

8 Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020; 14: 64-68 [PMID: 32037389 DOI: 10.5582/btt.2020.01630]

9 Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, Fang C, Huang D, Huang LQ, Huang Q, Han Y, Hu B, Hu F, Li BH; Li YR; Liang K, Lin LK, Luo LS, Ma J, Ma LL, Peng ZY, Pan YB, Pan ZY, Ren QX, Sun HM, Wang Y, Wang YY, Weng H, Wei CJ, Wu DF, Xia J, Xiong Y, Xu HB, Yao XM, Yuan YF, Ye TS, Zhang XC, Zhang YW, Zhang YM, Zhao Y, Zhao MJ, Zi H, Zeng XT, Wang XH; for the Zhongnan Hospital of Wuhan University Novel Coronavirus Prevention and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020; 7: 4 [PMID: 32029004 DOI: 10.1186/s40779-020-0233-6]

10 Zhang J, Wang S, Xue Y. Focal specimen diagnosis 2019 novel coronavirus-infected pneumonia. J Med Virol 2020; 92: 680-682 [PMID: 32124995 DOI: 10.1002/jmv.25742]

11 Khoury M, Cuenca J, Cruz FF, Figueroa FE, Roco PRM, Weiss DJ. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J 2020; 55 [PMID: 32263510 DOI: 10.1183/13993003.00858-2020]

12 Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 2010; 5: e10088 [PMID: 20436665 DOI: 10.1371/journal.pone.0010088]

13 Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci 2020; 11: 995-998 [PMID: 32167747 DOI: 10.1021/acscnemt.0c00225]

14 South AM, Brady TM, Flynn JT. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use during the Pandemic: The Pediatric Perspective. Hypertension 2020; 76: 16-22 [PMID: 32367746 DOI: 10.1161/HYPERTENSIONAHA.120.15291]

15 Trifirò G, Crisafulli S, Andò G, Racagni G, Drago F. Italian Society of Pharmacology. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? Drug Saf 2020; 43: 507-509 [PMID: 32303915 DOI: 10.1007/s40264-020-00935-2]

16 Lee KS. Pneumonia Associated with 2019 Novel Coronavirus: Can Computed Tomographic Findings Help Predict the Prognosis of the Disease? Korean J Radiol 2020; 21: 257-258 [PMID: 32056396 DOI: 10.3348/kjr.2020.0096]

17 PLOS ONE Staff. Correction: fractal feature of particle-size distribution in the rhizospheres and bulk soils during natural recovery on the loess plateau, China. PLoS One 2015; 10: e0138057 [PMID: 26368339 DOI: 10.1371/journal.pone.0138057]

18 Giuolo M, Maggioni D, Montroni I, Ugolini G, Capelli P, Ceppi L, Bonfanti P, Mariani A, Achilli F. Being a doctor will never be the same after the COVID-19 pandemic. Am J Med 2020; 133: 652 [PMID: 32240630 DOI: 10.1016/j.amjmed.2020.03.001]

19 Santini D, Tonini G. Brief letter of a doctor to his psychologist in the COVID-19 outbreak era. ESMO Open 2020; 5: e000801 [PMID: 32398253 DOI: 10.1136/esmoopen-2020-000801]

20 Cao H, Ruan L, Liu J, Liao W. The clinical characteristic of eight patients of COVID-19 with positive RT-PCR test after discharge. J Med Virol 2020; 92: 2159-2164 [PMID: 32410245 DOI: 10.1002/jmv.26001]

21 He J, Wu B, Chen Y, Tang J, Liu Q, Zhou S, Chen C, Qin Q, Huang K, Lv J, Peng D. Characteristic Electrocardiographic Manifestations in Patients With COVID-19. Can J Cardiol 2020; 36: 966.e1-966.e4 [PMID: 32299751 DOI: 10.1016/j.cjca.2020.03.028]

22 Wang H, Wei R, Rao G, Zhu J, Song B. Characteristic CT findings distinguishing 2019 novel coronavirus-infected pneumonia. Mil Med Res 2020; 7: 10.1002/jmv.25742

23 Lv B, Li Z, Chen Y, Long C, Fu X. Global COVID-19 fatality analysis reveals Hubei-like countries potentially with severe outbreaks. J Infect 2020; 81: e87-e88 [PMID: 32320605 DOI: 10.1016/j.jinf.2020.03.020]

24 Sun L, Ding MJ, Cai TC, Fan HJ, Gao HM, Zhang JP. Using a new plateau hyperbaric chamber to alleviate high altitude hypoxia: Rabbit and human studies. Am J Emerg Med 2017; 35: 1536-1541 [PMID: 28501324 DOI: 10.1016/j.ajem.2017.04.034]

25 Wei D, Wei L, Li X, Wang Y. Effect of Hypoxia on Ldhl-c Expression in Somatic Cells of Plateau Pika. Int J Environ Res Public Health 2016; 13 [PMID: 27490559 DOI: 10.3390/ijerph13080773]

26 Li YY, Liu FY, Hu L, Liu SM, Wu TY. [Comparative study of high altitude chronic hypoxia on renal function in yak and migratory cattle on Qinghai-Tibetan plateau]. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2016; 32: 440-443 [PMID: 29931848 DOI: 10.1345/j.cnki.cjaph.2016.05.014]

27 Wu H, Gu Q, Xie Y, Lou Z, Xue P, Fang L, Yu C, Jia D, Huang G, Zhu B, Schneider A, Blom J,
Lasch P, Borris R, Gao X. Cold-adapted Bacilli isolated from the Qinghai-Tibetan Plateau are able to promote plant growth in extreme environments. *Environ Microbiol* 2019; [PMID: 31233661 DOI: 10.1111/1462-2920.14722]

29 Ding Z, Li L, Wei R, Dong W, Guo P, Yang S, Liu J, Zhang Q. Association of cold temperature and mortality and effect modification in the subtropical plateau monsoon climate of Yuxi, China. *Environ Res* 2016; 150: 431-437 [PMID: 27376930 DOI: 10.1016/j.envres.2016.06.029]

30 Bing H, Wu Y, Zhou J, Li R, Luo J, Yu D. Vegetation and Cold Trapping Modulating Elevation-dependent Distribution of Trace Metals in Soils of a High Mountain in Eastern Tibetan Plateau. *Sci Rep* 2016; 6: 24081 [PMID: 27052807 DOI: 10.1038/srep24081]

31 Norsang G, Chen YC, Pingeou N, Dahlback A, Frette Ø, Kjeldstad B, Hamre B, Stamnes K, Stamnes JJ. Comparison of ground-based measurements of solar UV radiation at four sites on the Tibetan Plateau. *Appl Opt* 2014; 53: 736-747 [PMID: 24514192 DOI: 10.1364/AO.53.000736]

32 Ademola JA. Exposure to high background radiation level in the tin mining area of Jos Plateau, Nigeria. *J Radiol Prot* 2008; 28: 93-99 [PMID: 18309198 DOI: 10.1088/0952-4746/28/1/006]

33 Polkinghorne A, Branley J. Evidence for decontamination of single-use filtering facepiece respirators. *J Hosp Infect* 2020; 105: 663-669 [PMID: 32473179 DOI: 10.1016/j.jhin.2020.05.032]

34 Rathnasinghe R, Karlicek RF, Schotsaert M, Koffas MA, Arduni B, Jangra S, Wang B, Davis JL, Alnaggar M, Costa A, Vincent R, Garcia-Sastre A, Vashishth D, Balchandani P. Scalable, effective, and rapid decontamination of SARS-CoV-2 contaminated N95 respirators using germicidal ultraviolet C (UVC) irradiation device. *medRxiv* 2020 [PMID: 33052360 DOI: 10.1101/2020.05.20.2006953]

35 De Larochelambert Q, Marc A, Antero J, Le Bourg E, Toussaint JF. Covid-19 Mortality: A Matter of Vulnerability Among Nations Facing Limited Margins of Adaptation. *Front Public Health* 2020; 8: 604339 [PMID: 33330343 DOI: 10.3389/fpubh.2020.604339]

36 Earhart AP, Holliday ZM, Hofmann HV, Schrum AG. Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome. *New Microbes New Infect* 2020; 35: 100689 [PMID: 32355564 DOI: 10.1016/j.mnin.2020.100689]

37 Colla J, Rodos A, Seyller H, Weingart S. Fighting COVID-19 Hypoxia With One Hand Tied Behind Our Back: Blanket Prohibition of High-Flow Oxygen and Noninvasive Positive End-Expiratory Pressure in US Hospitals. *Ann Emerg Med* 2020; 75: 791-792 [PMID: 32471585 DOI: 10.1016/j.annemergmed.2020.04.015]
